| Filed On | Filing |
|---|---|
| 01 Oct 2026 |
8-K: Other Events
On October 1, 2026, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing the presentation of a poster at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seou... |
| 28 Sep 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer of Gain Therapeutics, Inc. (the “Company”), notified the Company of his intention to resign from hi... |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 17 Jul 2026 |
Form 4: Goldstein Dov A Md, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Nicaise Claude, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Islam Khalid, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Melincoff Gwen A, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Riley Jeffrey Scott, Director
Granted 25,000 Stock Option (right to buy) |
| 17 Jul 2026 |
Form 4: Hasler Hans Peter, Director
Granted 25,000 Stock Option (right to buy) |
| 16 Jul 2026 | 8-K: Other Events |
| 29 Jun 2026 | 8-K: Other Events |
| 25 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 26 May 2026 | 8-K: Other Events |
| 11 May 2026 | 10-Q |
| 11 May 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Apr 2026 | ARS |
| 28 Apr 2026 | DEFA14A |
| 28 Apr 2026 | Proxy statement: annual meeting on June 24, 2026 |
| 26 Mar 2026 |
Form 4: Mack Gene, Director
Granted 200,000 Employee Stock Option (right to buy) |
Loading...
